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Abstract
Background. Visceral adiposity index (VAI) is a new anthropometric indicator that makes it possible to 
define the risk of obesity-related cardiometabolic complications even before the diagnosis of metabolic 
syndrome.
Objectives. Evaluating the usefulness of VAI in order to differentiate metabolically unhealthy women 
(MU-PCOS) and defining the usefulness of this index in everyday practice.
Material and methods. A prospective study was conducted among 43 women who met the Rotterdam 
criteria for diagnosing polycystic ovarian syndrome. Body composition was measured using bioelectrical 
impedance analysis. Statistical analysis was performed using STATISTICA v. 10 and relevant statistical tests. 
The adopted significance level was p = 0.05.
Results. Based on the study results, a significant positive correlation was found between the value of VAI 
and the concentration of insulin (r = 0.33; p < 0.01), HOMA index (r = 0.46; p < 0.01) and FAI (r = 0.54; 
p < 0.01). It was also shown that there is a significant negative correlation between VAI and the concentra-
tion of SHBG (r = -0.53; p < 0.01) and HDL cholesterol (r = -0.88; p < 0.01). In the group of metabolically 
unhealthy women, the research showed a significantly higher value of free testosterone, SHGB, DHEAS and 
FAI (p < 0.05).
Conclusions. Visceral adiposity index makes it possible to introduce early prevention of metabolic dis-
orders (including cardiometabolic disorders), as well as to evaluate the increase of hyperandrogenemia in 
women with polycystic ovary syndrome. The use of the cut-off point of VAI = 1.675 is a simple way to 
evaluate women with MU-PCOS.
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Background
Visceral adiposity index (VAI) is a  recent anthropo-
metric indicator indirectly reflecting the risk of obesity-
related cardiometabolic complications. Its application 
allows early evaluation of such risk, even prior to diag-
nosing overt metabolic syndrome.1 VAI can be consid-
ered a marker of adipose tissue dysfunction as it provides 
reliable data when used in the general population and in 
patients with polycystic ovary syndrome, acromegaly, 
type 2 diabetes, viral hepatitis C, non-alcoholic fatty liver 
diseases.1 This index allows accurate identification of 
visceral adipose tissue in women with polycystic ovary 
syndrome, determining intra-abdominal adipose tissue 
content in a similar way to a computed tomography (CT) 
scan performed in this group of female patients.2 VAI is 
an empirical-mathematical model, gender-specific and 
based on anthropometric measurements, such as BMI 
and waist circumference, and biochemical parameters, 
namely triglyceride (TG) and high-density lipoprotein 
cholesterol (HDL-C) concentrations.3
Fig. 1 illustrates the formula of the visceral adiposity 
index for women.
Objectives
Application of the cut-off point for VAI = 1.675 in order 
to distinguish women with metabolically unhealthy poly-
cystic ovary syndrome (MU-PCOS) and to determine the 
usefulness of the index in question among women diag-
nosed with polycystic ovary syndrome in everyday clini-
cal practice.
Material and methods
The prospective study was conducted among 43 wom-
en hospitalized at the Department of Endocrinology 
and Gynecology of Silesian University, and fulfilling the 
Rotterdam criteria for diagnosing polycystic ovary syn-
drome. The diagnosis of the syndrome had to include at 
least 2 of the following 3 criteria: oligoovulation or an-
ovulation, clinical and/or biochemical hyperandrogen-
ism, polycystic ovaries on ultrasound after exclusion of 
other causes of the above-mentioned symptoms. The ex-
clusion criteria applied in the study were: diagnosis of 
androgen excess disorders (congenital or late-onset 
congenital adrenal hyperplasia, androgen-secreting tu-
mors, Cushing’s disease/syndrome, hyperprolactinemia, 
idiopathic hirsutism), uncontrolled thyroid disorders, 
mental disorders, morbid obesity (BMI  >  40  kg/m2), 
pendulous abdominal skin folds, hypertriglyceridemia, 
low-energy diet, use of hormonal contraception in the 
past 6 months, taking fibrates or steroids, and being over 
the age of 40.
Prior to conducting the actual studies, the consent of 
the Bioethics Committee was obtained, no. KNW/0022/
KB1/53/14, dated June 3rd, 2014. Body composition was 
evaluated by bioelectrical impedance analysis utilizing 
a Tanita BC-420 MA Body Composition Analyzer (prod-
uct in accordance with the Medical Device Directive 
MDD 93/42 EEC). The standard anthropometric mea-
surement method was applied for the circumference of 
the waist, hips, wrist, shoulder and calf. A  stadiometer 
(Tanita HR-100 Height Rod) was used to measure body 
height. Waist-to-hip ratio (WHR) was adopted in the 
study. It can be calculated by dividing the waist circum-
ference (in cm) at the umbilical level by the hip circum-
ference (in cm) at the superior iliac spine level. Values 
higher than or equal to 0.85 indicate abdominal obesity 
and lower than 0.85 gluteal-femoral obesity. The value of 
waist-to-height ratio (WHtR) was obtained by dividing 
the waist circumference (in cm) at the umbilical level by 
the body height (in cm). Results higher than 0.5 indicate 
increased risk of obesity-related cardiovascular diseases.
Blood samples were collected in the morning during 
routine patient examinations in the ward. The tests were 
performed by means of the immunoenzymatic method 
(ELISA) using commercial test kits in an accredited ana-
lytical laboratory monitored by the external quality as-
Fig.1. Waist circumference (cm), BMI (kg/m2), TG (mmol/L), HDL (mmol/L)
waist circumference TG 1.52
VAI =     
36.58 + (1.86  BMI) 0.81 HDL
     × ×     ×     
Polycystic ovary syndrome (PCOS) manifests itself in 
menstrual disorders, clinical and biochemical hyperan-
drogenism and polycystic ovaries on ultrasound. In ad-
dition, it is also responsible for higher risk of cardio-
vascular diseases, impaired glucose tolerance and type 
2 diabetes.4 Insulin resistance and android (abdominal) 
obesity in PCOS women are not always associated with 
increased BMI. Excess body weight is not necessary for 
increased cardiometabolic risk to occur in this group of 
patients, however it leads to the exacerbation of clini-
cal symptoms of the syndrome in question.5 Since VAI 
is a  simple and easy method for evaluation of cardio-
metabolic risk, it can be a  useful tool for the assess-
ment of metabolic risk related to visceral obesity both 
in everyday medical practice and in population studies. 
Values of VAI > 1.675 make it possible to differentiate 
women with metabolically unhealthy polycystic ovary 
syndrome (MU-PCOS) from women with metabolically 
healthy polycystic ovary syndrome (MH-PCOS). Never-
theless, the index should not be used for individuals who 
are under 16 years of age, who have morbid obesity (BMI 
> 40 kg/m2), who are diagnosed with pendulous abdom-
inal skin folds or hypertriglyceridemia, nor in subjects 
who are being treated with fibrates and/or are following 
a low-energy diet.1
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surance programs. Laboratory blood tests included com-
plete lipidogram, levels of glucose, total testosterone, 
free testosterone, sex hormone binding globulin (SHBG), 
dehydroepiandrosterone (DHEAS), insulin, homeostatic 
model assessment of insulin resistance (HOMA-IR), and 
free androgen index (FAI).
The studied women were divided into 2 groups with 
metabolically healthy polycystic ovary syndrome (MH-
PCOS; VAI < 1.675) and metabolically unhealthy polycys-
tic ovary syndrome (MU-PCOS; VAI > 1.675). The statis-
tical analysis of the obtained results was conducted with 
STATISTICA v. 10.0. The Shapiro-Wilk test was utilized 
to verify normal distribution for the analyzed variables. 
Statistical tests to verify particular study hypotheses were 
properly selected in order to reveal differences or correla-
tions between the variables. For the differences between 
the study groups to be determined, the following tests 
were applied: the Student’s t-test (normal distribution) 
and the Mann-Whitney U-test (abnormal distribution). 
The results showing normal distribution were expressed 
as an average value (x) ± standard deviation (SD). The pa-
rameters with abnormal distribution were expressed as 
median and interquartile ranges. For assessment of the 
correlations between the analyzed variables, the Spear-
man rank correlation was used. The significance level of 
p = 0.05 was adopted.
Results
The study was carried out in a  group of women at 
the age of 18–38 (26.52 ± 5.73). The average values of 
the selected anthropometric parameters were as fol-
lows: body weight 73.54 ± 19.07 kg; waist circumfer-
ence 87.07  ±  16.58  cm; BMI 27.16 ± 6.91 kg/m2; WHR 
0.82 ± 0.08; WHtR 0.53 ± 0.1; fat mass percentage (FM%) 
34.01 ± 9.7. Table 1 illustrates the detailed characteristics 
of the MH-PCOS and MU-PCOS women.
Significant differences were revealed between the study 
groups of women, which concerned the average values of 
the following anthropometric parameters and indicators: 
body weight, waist circumference, BMI, WHR, WhtR 
and FM%. The average values of the analyzed tests were 
significantly higher in the MU-PCOS group than in the 
MH-PCOS group (p < 0.01).
The study also revealed significant differences between 
the MH-PCOS and MU-PCOS groups with regard to the 
average values of the following biochemical studies: con-
centrations of triglycerides, HDL cholesterol, SHBG, free 
testosterone, DHEAS and HOMA-IR (p < 0.05) (Table 2).
The study involved a correlation analysis between VAI 
and the studied variables for the whole PCOS group 
(n = 43). The analysis showed a positive correlation be-
tween the VAI value and body weight (r = 0.69; p < 0.01), 
WHR (r = 0.67; p < 0.01), WHtR (r = 0.72; p < 0.01) and 
visceral adipose tissue (r = 0.69; p < 0.01), as well as FM% 
(r = 0.69; p < 0.01). The correlation analysis was also per-
formed for biochemical studies (Table 3).
It was found that, along with an increase in the VAI value, 
the concentrations of insulin, triglycerides, HOMA-IR and 
FAI also significantly increased (p < 0.05). A negative cor-
relation was reported between VAI and serum HDL cho-
lesterol and SHGB concentrations (p < 0.01). No significant 
Table 1. Comparison of data from patient groups before and after the operation
Parameters MH-PCOS (n = 28) MU-PCOS (n = 15) p-value
Age (years) 26 (22.5–31) 25.27 ± 5.57 0.3021
Body weight (kg) 61.3 (54.9–70.25) 89.8 (74–103.2) < 0.01
Waist 
circumference 
(cm)
79.52 ± 11.9 100.5 ± 16.03 < 0.01
BMI (kg/m2) 22.85 (20.7–25.25) 32.61 ± 6.44 < 0.01
WHR 0.78 ± 0.06 0.89 ± 0.08 < 0.01
WHtR 0.47 (0.43–0.52) 0.62 ± 0.09 < 0.01
FM% 29.77 ± 7.98 42.9 (37–46.1) < 0.01
FM% – fat mass percentage.
Table 2. Analysis of the differences of the average values of the selected 
biochemical studies between the groups of MH-PCOS and MU-PCOS 
women
Parameters MH-PCOS (n = 28) MU-PCOS (n = 15) p-value
Testosterone 
(nmol/L)
2.01 ± 0.73 2.15 (1.63–3.12) 0.1327
Free 
testosterone 
(pmol/L)
15.19 (11.13–30.93) 32.66 (17.86–44.83) < 0.05
SHBG 
(nmol/L)
60 ± 29.54 27.70 (18.25–52.60) < 0.05
DHEAS 
(umol/L)
8.36 ± 3.41 10.82 ± 3.21 < 0.05
FAI 3.3 (3.1–5.5) 6.65 (4.8–12.75) < 0.05
Glucose 
(mmol/L)
5.0 (4.67–5.22) 5.25 ± 0.5 0.0647
Insulin 
(pmol/L)
65.65 (43.05–87.54) 85.31 ± 37.02 0.2082
HOMA 1.66 (1.0–2.5) 2.72 ± 1.21 < 0.05
TC (mmol/L) 4.84 ± 0.63 4.56 ± 0.67 0.1729
HDL-C 
(mmol/L)
1.83 ± 0.39 1.16 (1.09–1.27) < 0.01
LDL-C 
(mmol/L)
2.64 ± 0.66 2.56 ± 0.68 0.7064
TG (mmol/L) 0.81 ± 0.26 1.6 (1.37–2.03) < 0.01
TC – total cholesterol.
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correlations were revealed between VAI and the concentra-
tions of glucose, complete cholesterol, LDL cholesterol, tes-
tosterone, free testosterone and DHEAS (p > 0.05).
Discussion
VAI, similarly to a computed tomography scan, is an ef-
fective indicator of visceral adipose tissue. This was con-
cluded by Jee-Young Oh et al., who had assessed the cor-
relation between VAI and insulin resistance in a  group 
of 180 Korean women with polycystic ovary syndrome. 
The  study revealed a  positive correlation between vis-
ceral fat area (VFA), measured by a  CT scan, and VAI 
(r = 0.57; p < 0.01).2 The authors of this manuscript found 
significant dependence between VAI and the indicator 
of visceral adipose tissue measured by the bioelectrical 
impedance analysis. In another study, which comprised 
a group of 193 women with PCOS, Androulakis II et al. 
observed a  significant positive correlation between VAI 
and the concentrations of insulin (r = 0.57; p < 0.01), SHBG 
(r = -0.22; p < 0.05) and HOMA-IR (r = 0.55, p < 0.01). 
The  same observation was made by the authors of this 
paper. The authors of the quoted study revealed signifi-
cantly higher values of VAI and HOMA in the group of 
PCOS women with menstrual disorders versus the female 
group with normal ovulation.7 In the research conducted 
by the authors of this manuscript, the studied women 
were not divided according to menstrual disorders.
Amato MC et al., relying on studies conducted in a group 
of 224 women with PCOS, found that in addition to the fast-
ing plasma glucose level, VAI value and DHEAS concentra-
tion can also be considered useful in determining the risk 
of diabetes in the screening tests for all women with poly-
cystic ovary syndrome.8 The authors of this manuscript did 
not reveal a  significant dependence between VAI and the 
fasting plasma glucose level. Such a  correlation, however, 
was found between insulin and HOMA concentrations 
(p < 0.05). Moreover, a correlation analysis between VAI and 
FAI was performed. On the basis of the results obtained, it 
can be claimed that the index in question is also an effec-
tive tool in assessing the severity of hyperandrogenemia in 
PCOS women. The correlation results between VAI and FAI 
have not been published by other researchers as yet. Very 
few studies have evaluated the usefulness of VAI in PCOS 
women. Therefore, it is necessary to carry out reliable, large 
population-based studies among European women diag-
nosed with polycystic ovary syndrome.
Conclusions
Following the studies conducted by the authors of this 
manuscript, it may be concluded that utilizing VAI dur-
ing routine medical examinations makes possible early 
prevention of metabolic disorders (including cardiometa-
bolic disorders), as well as assessment of hyperandrogen-
emia severity in women with polycystic ovary syndrome. 
The cut-off point for VAI = 1.675 is an easy tool for evalu-
ating women with metabolically unhealthy polycystic 
ovary syndrome (MU-PCOS).
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TG (mmol/L) 0.94 < 0.01
SHBG (nmol/L) -0.53 < 0.01
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Free testosterone (pmol/L) 0.30 0.0507
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